The PurpleLab

Life Sciences

White Papers

New Treatments Hold Significant Promise, but are Marketing Teams Helping Life Sciences Companies Deliver on this Potential? Life Sciences Download

Webinars

Join the PurpleLab team in this on-demand webinar discussing how Real-World Data can address the FDA mandate to develop a Race and Ethnicity Diversity Plan in clinical trials. Shannon LaRusso, SVP of Product Management, and Russell Robbins, MD, CMIO discuss:

Solution Sheets

CLEAR Claims Life Sciences Life Sciences Download

Solution Sheets

Life Science Package Life Sciences Download

Solution Sheets

Learn more about what PurpleLab can do for your Clinical Trials Life Sciences Download

Blog

Osteoporosis and low bone mass affect almost 54 million people in the US, placing them at risk for hip, spine, wrist fractures, permanent pain, limited mobility, and increased morbidity and mortality. The disease affects people of all races, ethnicities, and gender, although significant variation within these groups does exist. For the over fifty population, osteoporosis…

Blog

Colorectal Cancer Awareness Month is observed in March to highlight the importance of screening for colorectal cancer, as well as to promote healthy lifestyle habits that can decrease a person’s risk of developing cancer of the colon, rectum or anus – the three distinct cancer types referred to as colorectal cancer (CRC). CRC Is the…

Blog

Over the last decade, the life sciences industry has used digital advertising at an increasing rate to engage with patients throughout the drug development life cycle. From creating disease state awareness, to driving drug adherence, the trend particularly accelerated during 2020 and 2021, as pharmaceutical brands looked for ways to stay engaged with their patients…

White Papers

Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year.